Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

INTERMIN RESOURCES LIMITED (Company)

ABN

88 007 761 186

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- †Class of *securities issued or to be issued
- a) Fully paid ordinary shares (Shares)
- b) Unlisted options to acquire Shares at \$0.2912 per option expiring on 9 December 2019
- Unlisted options to acquire Shares at \$0.6988 per option expiring on 28 February 2020
- Number of *securities issued or to be issued (if known) or maximum number which may be issued
- a) Approximately 192,586,000 Shares (subject to adjustment for rounding and assuming no MacPhersons options are exercised prior to the Scheme record date). The exact number of Shares will be confirmed on the implementation date of MacPhersons Resources Limited's (MacPhersons) proposed scheme of arrangement first announced to ASX on 11 December 2018 (Scheme).
- b) 2,743,184 unlisted options expiring on 9 December 2019 (assuming no MacPhersons options are exercised prior to the Scheme record date).
- c) 219,456 unlisted options expiring on 28 February 2020 (assuming no MacPhersons options are exercised prior to the Scheme record date).

⁺ See chapter 19 for defined terms.

- 3 Principal of terms the +securities if options, (e.g. exercise price and expiry date; if partly paid +securities, the amount outstanding and due payment; dates for if +convertible securities, the conversion price and dates for conversion)
- a) Fully paid ordinary shares
- b) Each unlisted option shall entitle the holder to acquire one Share exercisable at \$0.2912 with an expiry date of 9 December 2019
- Each unlisted option shall entitle the holder to acquire one Share exercisable at \$0.6988 with an expiry date of 28 February 2020
- 4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

 Yes, the Shares shall rank equally in all respects with existing fully paid ordinary shares in the Company

If the additional *securities do not rank equally, please state:

- b) No, the options will not rank equally with an existing class of quoted securities and will not confer any right to participate in dividends or interest payments of the Company. Any Shares allotted upon exercise of the options will rank equally in all respects with existing fully paid ordinary shares in the Company.
- the date from which they do
- c) No, the options will not rank equally with an existing class of quoted securities and will not confer any right to participate in dividends or interest payments of the Company. Any Shares allotted upon exercise of the options will rank equally in all respects with existing fully paid ordinary shares in the Company.
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

the extent to which they do

- not rank equally, other than in relation to the next dividend, distribution or interest payment
- 5 Issue price or consideration

AUO BSN IBUOSIBO 10-

As set out in the Scheme booklet announced by MacPhersons (ASX: MRP) and released on the Company's ASX announcement platform (ASX: IRC) on 17 April 2019, the Shares are being issued in consideration for the transfer of MacPhersons shares at a ratio of 1 new Share for every 1.8227 MacPhersons shares held by MacPhersons shareholders on the record date of the Scheme (anticipated to be 11 June 2019).

The options in 1 (b) and (c) above are being issued in consideration for the cancellation of MacPhersons options at a ratio of 1 new option for every 1.8227 MacPhersons options cancelled on the implementation date of the Scheme (anticipated to be 14 June 2019).

6 Purpose of the issue
(If issued as consideration for
the acquisition of assets,
clearly identify those assets)

The Shares and options will be issued pursuant to the Scheme. The issue of Shares and options remains subject to implementation of the Scheme.

⁺ See chapter 19 for defined terms.

6	that	er approval under rule	Yes
	6h <i>ii</i> the s	es, complete sections 6b – n relation to the *securities subject of this Appendix 3B, comply with section 6i	
6		date the security holder lution under rule 7.1A was sed	27 November 2018
6	with	nber of *securities issued out security holder approval er rule 7.1	Assuming successful implementation of the Scheme, approximately 2,962,640 unlisted options (subject to adjustment for rounding and assuming no existing MacPhersons options are exercised before the Scheme record date)
6	with	nber of *securities issued security holder approval er rule 7.1A	Nil
6	with unde spec appr	aber of *securities issued security holder approval er rule 7.3, or another sific security holder soval (specify date of sting)	Nil
6		nber of *securities issued er an exception in rule 7.2	Assuming successful implementation of the Scheme, approximately 192,586,000 Shares (subject to adjustment for rounding and assuming no MacPhersons options are exercised prior to the Scheme record date)
6	7.1A 75% calc Inclu both sour	securities issued under rule at was issue price at least of 15 day VWAP as ulated under rule 7.1A.3? The sude the tiesue date and values. Include the compact of the VWAP ulation.	Not applicable.
6	rule cons whic cons	ecurities were issued under 7.1A for non-cash sideration, state date on the valuation of sideration was released to Market Announcements	Not applicable.

⁺ See chapter 19 for defined terms.

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

Assuming successful implementation of the Scheme, approximately 192,586,000 Shares and 2,962,640 unlisted options will be issued (subject to adjustment for rounding and assuming no existing MacPhersons options are exercised prior to the Scheme record date).

If the Scheme is implemented and the above securities are issued, then the Company's placement capacity will be:

7.1 - 61,233,529

7.1A - 42,797,446

7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

Expected to be 14 June 2019 (updated Appendix 3B to be lodged on or about the issue date)

8 Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)

Number	+Class
After implementation of	Fully Paid Ordinary
the Scheme, it is	Shares
anticipated that	
427,974,464 Shares	
will be on issue	
(comprising	
235,388,464 Shares	
currently on issue and	
192,586,000 Shares to	
be issued (subject to	
adjustment for rounding	
and assuming no	
existing MacPhersons	
options are exercised	
prior to the Scheme	
record date).	

9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)

	101
Number	⁺ Class
500,000	Unlisted Options – Exercise Price \$0.25 Expiry 31 August 2019 (IRCAI)
2,800,000	Class D Performance Rights expiring 1 July 2019 (subject to 6 months voluntary escrow)
2,800,000	Class E Performance Rights expiring 1 July 2020 (subject to 6 months voluntary escrow)
	The following options are proposed to be issued on implementation of the Scheme:
2,743,184	Unlisted Options – Exercise Price \$0.2912 Expiry 9 December 2019
219,456	Unlisted Options – Exercise Price \$0.6988 Expiry 28 February 2020

⁺ See chapter 19 for defined terms.

10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	Not applicable.

Part 2 - Pro rata issue

11	required?	Not applicable.
12	Is the issue renounceable or non-renounceable?	Not applicable.
13	Ratio in which the *securities will be offered	Not applicable.
14	*Class of *securities to which the offer relates	Not applicable.
15	⁺ Record date to determine entitlements	Not applicable.
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	Not applicable.
17	Policy for deciding entitlements in relation to fractions	Not applicable.
18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	Not applicable.
19	Closing date for receipt of acceptances or renunciations	Not applicable.
20	Names of any underwriters	Not applicable.
21	Amount of any underwriting fee or commission	Not applicable.
22	Names of any brokers to the issue	Not applicable.
23	Fee or commission payable to	Not applicable.

⁺ See chapter 19 for defined terms.

24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	Not applicable.
25	If the issue is contingent on security holders' approval, the date of the meeting	Not applicable.
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	Not applicable.
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	Not applicable.
28	Date rights trading will begin (if applicable)	Not applicable.
29	Date rights trading will end (if applicable)	Not applicable.
30	How do security holders sell their entitlements <i>in full</i> through a broker?	Not applicable.
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	Not applicable.
32	How do security holders dispose of their entitlements (except by sale through a broker)?	Not applicable.
33	†Issue date	Not applicable.

⁺ See chapter 19 for defined terms.

34	Type of *securities (tick one)
(a)	*Securities described in Part 1
(b)	All other *securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
Enti	ties that have ticked box 34(a)
Addi	tional securities forming a new class of securities
Tick to docum	o indicate you are providing the information or ments
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional *securities
Enti	ties that have ticked box 34(b)
38	Number of *securities for which *quotation is sought
39	+Class of +securities for which quotation is sought

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

⁺ See chapter 19 for defined terms.

	If the additional *securities do not rank equally, please state: the date from which they do the extent to which they participate for the next		
	dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	Number	+Class

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return
 the *securities to be quoted under section 1019B of the
 Corporations Act at the time that we request that the *securities be
 quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

	Bíanca Taveira	
Sign here:		Date: 18 April 2019
	(Company secretary)	

Print name: BIANCA TAVEIRA

⁺ See chapter 19 for defined terms.

Appendix 3B - Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	226,992,119	
Add the following:	Rule 7.2 Exception 4	
Number of fully paid +ordinary securities	200,000 issued on 30 April 2018	
issued in that 12 month period under an exception in rule 7.2	4,250,000 issued on 31 July 2018	
Number of fully paid +ordinary securities issued in that 12 month period with	287,500 issued on 2 & 3 August 2018	
shareholder approval	120,000 issued on 8 August 2018	
Number of partly paid +ordinary	312,500 issued on 14 & 15 August 2018	
securities that became fully paid in that 12 month period	3,226,345 issued on 31 August 2018	
Note: Include only ordinary securities here –	Rule 7.2 Exception 5	
other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items	192,586,000 Shares (being the proposed issued of Shares set out in 1(a) of this Appendix 3B	
Subtract the number of fully paid *ordinary securities cancelled during that 12 month period	Nil	
"A"	427,974,464	

⁺ See chapter 19 for defined terms.

	T
"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	64,196,169
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	2,962,640 options (being the proposed issued of options set out in 1 (b) & (c) of this
 Under an exception in rule 7.2 	Appendix 3B)
• Under rule 7.1A	
 With security holder approval under rule 7.1 or rule 7.4 	
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
"C"	2,962,640
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	B"] to calculate remaining
"A" x 0.15	64,196,169
Note: number must be same as shown in Step 2	
Subtract "C"	2,962,640
Note: number must be same as shown in Step 3	
Total ["A" x 0.15] – "C"	61,233,529
	[Note: this is the remaining placement capacity under rule 7.1]

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	42,797,446	
Step 3: Calculate "E", the amount of 7.1A that has already been used	placement capacity under rule	
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Nil	
Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items		
"E"	Nil	

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A "A" x 0.10 Note: number must be same as shown in Step 2 Subtract "E" Nil Note: number must be same as shown in Step 3 Total ["A" x 0.10] – "E" 42,797,446 Note: this is the remaining placement capacity under rule 7.1A

⁺ See chapter 19 for defined terms.